Recent developments in human cytomegalovirus diagnosis

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 3, 2007, Pages 427-439

  Halwachs Baumann, Gabriele ^a  

^a Krankenhaus Steyr   (Austria)

Author keywords

AIDS; Antigenemia; Congenital HCMV; HCMV diagnosis; Immunological monitoring; Molecular based assays; Resistance testing; Serology; Transplantation

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CIDOFOVIR; CORTICOSTEROID; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; DNA POLYMERASE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; HLA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIGEN DETECTION; BLOOD ANALYSIS; BODY FLUID; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA EXTRACTION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HEMAGGLUTINATION TEST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; LUNG LAVAGE; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; RADIOIMMUNOASSAY; RECIPIENT; RETINITIS; REVIEW; RISK ASSESSMENT; RNA ANALYSIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; URINALYSIS; VERTICAL TRANSMISSION; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS RESISTANCE; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; PATHOGENICITY; SECRETIONS; TRANSPLANTATION; VIROLOGY;

BODILY SECRETIONS; BODY FLUIDS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; RNA, VIRAL; SEROLOGIC TESTS; TRANSPLANTATION;

EID: 34447266693     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.3.427     Document Type: Review

References (91)

1. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin. Infect. Dis. 43, 1143-1151 (2006).
2. Ho M. Cytomegalovirus, Biology and Infection. Plenum Medical Book Company, NY, USA (1991).
3. Chan G, Hemmings DG, Yurochko AD, Guilbert LJ. Human cytomegalovirus-caused damage to placental trophoblasts mediated by immediate-early gene-induced tumor necrosis factar-α. Am. J. Pathol. 161, 1371-1381 (2002).
4. Calquist JF, Edelman L, Bennion DW, Anderson JL. Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-κB. J. Infect. Dis. 179, 1094-1100 (1999).
5. Halwachs-Baumann G, Weihrauch G, Gruber HJ, Desoye G, Sinzger CH. hCMV induced IL-6 release in trophoblast and trophoblast like cells. J. Clin. Virol. 37, 91-97 (2006).
6. Halwachs-Baumann G. The congenital cytomegalobirus infection: virus-host interaction for defense and transmission. Curr. Pharm. Biotechnol. 7(4), 303-312 (2006).
7. Snydman DR. Epidemiology of infections after solid-organ transplantation. Clin. Infect. Dis. 33(Suppl. 1), S5-S8 (2001).
8. Kramer MR, Marshall SE, Starnes VA, Gamberg P, Amitai Z, Theodore J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch. Intern. Med. 153(17), 2010-2016 (1993).
9. Snydman DR. Infection in solid organ transplantation. Transpl. Infect. Dis. 1(1), 21-28 (1999).
10. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am. J. Respir. Crit. Care Med. 170, 22-48 (2004).
11. Falagas ME, Vardakas KZ. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients. Clin. Microbiol. Infect. 12, 603-605 (2006).
12. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Michelson S, Plotkin SA (Eds). Excerpta Medica, Amsterdam, The Netherlands 233-237 (1993).
13. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J. Clin. Virol. 35, 474-477 (2006).
14. van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin. Infect. Dis. 33(Suppl. 1), S32-S37 (2001).
15. Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 84, 71-79 (1998).
16. Ljungman P, Perez-Bercoff L, Jonsson J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91(1), 78-83 (2006).
17. Einsele B, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the indicence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86(7), 2815-2920 (1995).
18. Nichols WG, Corey L, Gooley T. Rising pp65 antigenaemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97(4), 867-874 (2001).
19. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viraemia. J. Infect. Dis. 162, 373-380 (1990).
20. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 228(13), 853-860 (1998).
21. Springer KL, Weinberg A. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J. Antimicrob. Chemother. 54(3), 582-586 (2004).
22. Griffiths P. Cytomegalovirus infection of the central nervous system. Herpes 11 (Suppl. 2), 95A-104A (2004).
23. Burny W, Liesnard C, Donner C, Marchant A. Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection. Expert Rev. Anti Infect. Ther. 2(6), 881-894 (2004).
24. Halwachs-Baumann G, Genser B. Die konnatale Zytomegalievirusinfection. Epidemiologie - Diagnose - Therapie. Springer Verlag Wien, NY, USA (2003).
25. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 353(13), 1350-1362 (2005).
26. Kimberlin DW, Lin CY, Sanchez PJ et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143(1), 16-25 (2003).
27. Booth JC, Hannington G, Bakir TM et al. Comparison of enzyme-linked immunosorbent assay, radioimmunoassay, complement fixation, anticomplement immunofluorescence and passive haemagglutination techniques for detecting cytomegalovirus IgG antibody. J. Clin. Pathol. 35, 1345-1348 (1982).
28. Grint PC, Ronalds CJ, Kangro HO et al. Screening tests for antibodies to cytomegalovirus: an evaluation of five commercial products. J. Clin. Pathol. 76, 309-319 (1985).
29. Grillner L. Screening of blood donors for cytomegalovirus (CMV) antibodies: an evaluation of different tests. J. Virol. Methods 17(1-2), 133-139 (1987).
30. Gutierrez J, Maroto MC. A comparison of two ELISA methods for the investigation of anti-cytomegalovirus IgG antibodies. Microbios 90(364-365), 151-154 (1997).
31. Genser B, Truschnig-Wilders M, Stunzner D, Landini MP, Halwachs-Baumann G. Evaluation of five commercial enzyme immunoassays for the detection of human cytomegalovirus-specific IgM antibodies in the absence of a commercially available gold standard. Clin. Chem. Lab. Med. 39(1), 62-70 (2001).
32. Lang D, Vornhagen R, Rothe M, Hinderer W, Sonneborn HH, Plachter B. Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers. Clin. Diagn. Lab. Immunol. 8(4), 747-756 (2001).
33. Maine GT, Lazzarotto T, Landini MP. New developments in the diagnosis of maternal and congenital CMV infection. Expert Rev. Mol. Diagn. 1(1), 19-29 (2001).
34. Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis. 178(5), 1233-1243 (1998).
35. Lazzarotto T, Barielli L, Lanari M et al. Congenital cytomegalovirus infection: recent advances in the diagnosis of maternal infection. Hum. Immunol. 65, 410-415 (2004).
36. Lazzarotto T, Varani S, Spezzacatena P et al. Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus. Viral Immunol. 13(1), 137-141 (2000).
37. Lazzarotto T, Varani S, Spezzacatena P et al. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenaemia in solid organ transplant recipients. J. Infect. Dis. 178(4), 1145-1149 (1998).
38. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J. Infect. Dis. 190(11), 1908-1912 (2004).
39. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infection. Herpes 10(3), 60-65 (2003).
40. - transplant recipients. Am. J. Transplant. 5, 1065-1070 (2005).
41. Carman B. Molecular techniques should now replace cell culture in diagnostic virology laboratories. Rev. Med. Virol. 11(6), 347-349 (2001).
42. Ogilvie M. Molecular techniques should not now replace cell culture in diagnostic virology laboratories. Rev. Med. Virol. 11(6), 351-354 (2001).
43. Wallace PS. Linkage between the journal and quality control molecular diagnostics (QCMD). J. Clin. Virol. 27, 211-212 (2003).
44. Nye MB, Leman AR, Meyer ME, Menegus MA, Rothber PG. Sequence diversity in the glycoprotein B gene complicates real-time PCR assays for detection and quantification of cytomegalovirus. J. Clin. Microbiol. 43(10), 4968-4971 (2005).
45. Schäfer P, Tenschert W, Schröter M, Gutensohn K, Laufs R. False-positive results of plasma PCR for cytomegalovirus DNA due to delayed sample preparation. J. Clin. Microbiol. 38(9), 3249-3253 (2000).
46. Schäfer P, Tenschert W, Kutensohn K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J. Clin. Microbiol. 35, 741-744 (1997).
47. Razonable RR, Brown R, Wilson J et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73(6), 968-973 (2002).
48. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. Herpes 11(3), 77-86 (2004).
49. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplant Consensus Workshop on cytomegalovirus management in solid organ transplantation final report. Am. J. Transplant. 5, 218-227 (2005).
50. Lehto JT, Lemström K, Halme M et al. A prospective study comparing cytomegalovirus antigenaemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients. Transpl. Int. 18, 1318-1327 (2005).
51. Martin-Dávila P, Fortún J, Gutiérrez C et al. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value. J. Clin. Virol. 33, 138-144 (2005).
52. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes 13(1), 4-11 (2006).
53. Halwachs-Baumann G, Wilders-Truschnig M, Enzinger G et al. Cytomegalovirus diagnosis in renal and bone marrow transplant recipients: the impact of molecular asays. J. Clin. Virol. 20, 49-57 (2001).
54. Chemaly RF, Yen-Lieberman B, Castilla EA et al. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J. Clin. Microbiol. 42(5), 2168-2172 (2004).
55. Chemaly RF, Yen-Lieberman B, Chapman J et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am. J. Transplant. 5, 544-548 (2005).
56. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J. Infect. Dis. 190, 1076-1083 (2004).
57. Meylan PRA, Zanetti G. Cytomegalovirus load in bronchoalveolar lavage fluid: a clue to the diagnosis of cytomegalovirus pneumonia? J. Infect. Dis. 191, 2153 (2005).
58. Halwachs-Baumann G, Genser B, Pailer S et al. Human cytomegalovirus load in various body fluids of congenitally infected newborns. J. Clin. Virol. 25, 81-87 (2002).
59. Tarrago D, Mateos ML, Avellón A, Pérez-Vázquez MD, Tenorio A. Quantitation of cytomegalovirus DNA in cerebrospinal fluid and serum specimens from AIDS patients using a novel highly sensitive nested competitive PCR and the Cobas Amplicor CMV Monitor. J. Med. Virol. 72, 249-256 (2004).
60. Stanojevic M, Zerjav S, Jevtovic D, Salemovic D, Ranin J. CMV DNA in blood and CSF of HIV infected patients. Virus Res. 85, 117-122 (2002).
61. Kojima T, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H. Cytomegalovirus infection in ulcerative colitis. Scand. J. Gastroenterol., 41(6), 706-711 (2006).
62. Cottone M, Pietrosi G, Martorana G et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am. J. Gastroenterol. 96(3), 773-773 (2001).
63. Wada Y, Matsui T, Matake H et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis. Colon Rectum 46(10 Suppl.), S59-S65 (2003).
64. Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl. Environ. Microbiol. 63, 3741-3751 (1997).
65. Boom R, Sol C, Weel J et al. Detection and quantitation of human cytomegalovirus DNA in faeces. J. Virol. Methods 84, 1-14 (2000).
66. Keightley MC, Rinaldo C, Bullotta A, Dauber J, St George K. Clinical utility of CMV early and late transcript detection with NASBA in bronchoalveolar lavages. J. Clin. Virol. 37, 258-264 (2006).
67. Mengoli C, Cusinato R, Biasolo MA, Cesaro S, Parolin C, Palù G. Assessment of CMV load in solid organ transplant recipients by pp56 antigenaemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J. Med. Virol. 74, 78-84 (2004).
68. Szczepura A, Wetmoreland D, Vinogradova Y, Fox J, Clark M. Evaluation of molecular techniques in prediction and diagnosis of cytomegalovirus disease in immunocompromised patients. Health Technol. Assess. 10(10), 1-176 (2006).
69. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J. Clin. Microbiol. 40(3), 746-752 (2002).
70. Gilbert C, Boivin G. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS 17, 337-341 (2003).
71. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J. Med. Virol. 74, 85-93 (2004).
72. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenaemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes. J. Clin. Microbiol. 36, 3585-3589 (1998).
73. St George K, Boyd MJ, Lipson SM et al. A multisite trial comparing two cytomegalovirus (CMV) pp65 antigenaemia test kits, biotest CMV Brite and Bartels/Argene CMV Antigenaemia. J. Clin. Microbiol. 38(4), 1430-1433 (2000).
74. Zweygberg Wirgart B, Claesson K et al. Cytomegalovirus (CMV) DNA amplification from plasma compared with CMV pp65 antigen (ppUL83) detection in leukocytes for early diagnosis of symptomatic CMV infection in kidney transplant patients. Clin. Diagn. Virol. 7, 99-110 (1996).
75. Hernando S, Folueira L, Lumbreras C et al. Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenaemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplant Proc. 37, 4094-4096 (2005).
76. Herrmann B, Larsson VC, Rubin CJ. Comparison of a duplex quantitative real-time PCR assay and the COBAS Amplicor CMV Monitor Test for detection of cytomegalovirus. J. Clin. Microbiol. 42(5), 1909-1914 (2004).
77. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antivir. Res. 71(2-3), 154-163 (2006).
78. Jabs DA, Enger C, Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob. Agents Chemother. 42(9), 2240-2244 (1998).
79. Chou S, Marousek G, Parenti DM et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J. Infect. Dis. 178 (2), 526-530 (1998).
80. Abraham B, Lastere S, Reynes J, Bibollet-Ruche F, Vidal N, Segondy M. Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir. J. Clin. Virol. 13, 141-148 (1999).
81. Gilbert C, Handfield J, Toma E, Lalonde R, Bergeron MG, Boivin G. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12, 125-129 (1998).
82. Lee GC, Lee DG, Choi SM et al. Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir. J. Clin. Microbiol. 43(10), 5003-5008 (2005).
83. McSharry JJ, Lurain NS, Drusano GL et al. Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 42(9), 2326-2331 (1998).
84. Prix L, Maierl J, Jahn G, Hamprecht K. A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. J. Clin. Virol. 11(1), 29-37 (1998).
85. Chou S, Lurain NS, Weinberg A et al. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob. Agents Chemother. 43(6), 1500-1502 (1999).
86. Jabs DA, Martin BK, Ricks MO, Forman MS. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome. J. Infect. Dis. 193, 1728-1737 (2006).
87. Ljungman P. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients. J. Clin. Virol. 35, 493-495 (2006).
88. Harari A, Zimmerli SC, Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum. Immunol. 65, 500-506 (2004).
89. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. Biodrugs 17(5), 325-338 (2003).
90. + T cells. J. Gen. Virol. 86, 275-284 (2005).
91. + T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur. J. Immunol. 35, 1795-1804 (2005).